" "
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lophius Biosciences Concludes TB Detection Trials

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
Company achieves first clinical Proof of Principle for T-Track® TB for detection of active tuberculosis and receives research funding.

Lophius Biosciences has reported its first successfully concluded clinical Proof of Principle study with respect to detection of active tuberculosis (TB) using its novel T-Track® TB test which is based on Lophius Biosciences proprietary Reverse T Cell Technology (RT Technology).

The clinical Proof of Principle was concluded in India with a cohort of 44 patients. Results demonstrate that the T-Track® TB test was able to detect active TB in in 10 of 12 non-treated patients. Besides its high sensitivity and specificity the T-Track® TB test also demonstrated a remarkably short turnaround time of 2 days which compares favorably to currently used classical detection methods. In summary, these results imply that the T-Track® TB test could represent an innovative and fast detection approach for this area of strong medical need.

For further test development Lophius Biosciences has been awarded research funding of 140K EUR under the scope of the ZIM-solo-program from the German government. This funding should help to broaden the scope of the T-Track® TB tests with respect to detection of latent TB and potential patient-monitoring of treated TB subjects. The company will present first results at Medica mid November 2012 in Düsseldorf.

"We are very pleased to have accomplished clinical Proof of Principle for our second proprietary technology platform. Our short-term goal is geared towards test optimization and further validation in a bigger patient cohort" said Dr. Michael Lutz, CEO of Lophius Biosciences.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
Dr. Phelps has longstanding experience in business development and licensing.
Wednesday, December 04, 2013
Lophius Biosciences Joins NEU² Program
Company receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis.
Wednesday, June 19, 2013
Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Achieves First Clinical Proof of Principle for T-Track® TB
Clinical proof of principle for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification
Company has received CE-marking for its T-Track® CMV and T-Track® EBV tests.
Friday, June 01, 2012
Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Financial investors such as S-Refit, High-Tech Gründerfonds and Bayernkapital participated in this financing round.
Tuesday, July 19, 2011
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Unique Mechanism for a High-Risk Leukemia
Researchers uncovered the aberrant mechanism underlying a notoriously treatment-resistant acute lymphoblastic leukemia subtype; findings offer lessons for understanding all cancers.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!